Short Communication

Modification of second cancer risk after malignant melanoma by parental history of cancer

H Zhang1, J Lorenzo Bermejo*,1, J Sundquist2 and K Hemminki1,2

1Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 2Center for Family and Community Medicine, Karolinska Institute, Alfred Nobels allé 12, 14183 Huddinge, Sweden

The Swedish Family-Cancer Database was used to quantify the incidence of second tumours in melanoma patients with a parental history of cancer. Patients with parents affected by melanoma showed a 32.3-fold risk of second primary melanomas, which was greater than a multiplicative interaction.

British Journal of Cancer (2008) 99, 536–538. doi:10.1038/sj.bjc.6604489 www.bjcancer.com
Published online 15 July 2008
© 2008 Cancer Research UK

Keywords: familial risk; second cancer; genetic susceptibility; melanoma

Compared with other skin cancers, cutaneous melanoma (CM) is a rare disease, with an incidence rate of 14 cases per 100 000 in Sweden, one of the highest rates in Europe (de Vries and Coebergh, 2004). In contrast, CM is responsible for 80% of all skin cancer-related deaths (Miller and Mihm, 2006). The improvements in survival after melanoma have resulted in an increased incidence of subsequent primary tumour survival (Bhatia et al, 1999). Melanoma patients are prone to develop second tumours in the breast, prostate, kidney and skin, and particularly, second primary melanomas (Schmid-Wendtner et al, 2001; Goggins and Tsao, 2003), but those with a parental history of cancer have not been ascertained separately. The present population-based study investigates the risk of type-specific second tumours after diagnosis of melanoma and expands on the familial risk of subsequent cancers. Apart from its importance for clinical counselling and prevention, an understanding of the role of parental history in multiple cancers may help to understand cancer aetiology.

MATERIALS AND METHODS

The Swedish Family-Cancer Database, which was created in 1995 and last updated in 2006, includes a total of 11.5 million individuals. The Database covers offspring born or immigrated after 1931 with information on biological parents (Hemminki et al, 2006). In this study, cancers were classified according to the 4-digit diagnostic code from the seventh version of the International Classification of Disease (ICD-7). Tumours are compulsorily reported in Sweden and the agreement between clinical and cytological or histological diagnoses is close to 100%.

In the present retrospective cohort study, follow-up started at diagnosis of melanoma in a member of the offspring generation and it ended at occurrence of death, emigration, the diagnosis of any subsequent malignancy or 31 December 2004 (close date of the study). Two types of parental history were investigated: a parental history of melanoma (one of the two parents of the individual diagnosed with malignant melanoma) and a concordant parental history (one of the parents affected by the same type of cancer as the second primary cancer in the offspring). Standardized incidence ratios (SIR) were used to measure the relative risk of second cancers and they were calculated as the ratio of observed (O) to expected (E) number of cases. The expected numbers were computed from the first primary cancer incidence rates taking into account age (5-year intervals), region (four regions), calendar period (1960–1964, 1965–1969, …, 2000–2004) and socio-economic status (six groups). A Poisson distribution of the number of cases was assumed. Multiplicative interaction indexes (MIIs) and interaction contrast ratios (ICRs) were used to investigate the possible interaction between ‘individual history of melanoma’ and ‘parental history of cancer’. If SIRmelanoma represents the relative risk of cancer after melanoma, SIRph the relative risk in individuals with a parental history of melanoma and the relative risk in melanoma patients with a parental history, MII = SIRmelanoma/SIRph and ICR = SIRmelanomaxph/SIRmelanoma–SIRph + 1. MII suggests departure from multiplicativity and ICR0 indicates departure from additivity. Confidence intervals and P-values for MII and ICR were calculated by bootstrapping using 10 000 replications. All statistical analyses were carried out in SAS 9.1.

RESULTS

We identified 15 581 individuals in the offspring generation diagnosed with malignant melanoma before the age of 73 years (registration of individuals started in 1931 and the last update of the Database includes cancers diagnosed before year 2004). Among the patients, 1156 developed a subsequent cancer. Table 1 shows the SIRs for sites where at least 10 cases were observed. Compared with the general Swedish population, an increased risk of second cancer was observed for the breast (1.35), prostate (1.22), skin (melanoma 9.03 and squamous cell 3.48) and nervous system (1.66). Lymphohematopoietic neoplasms were also in excess,
mostly because of an increased risk of non-Hodgkin’s lymphoma with an SIR of 1.60. A parental history of melanoma increased the risk of second melanoma to an SIR of 32.3. The analysis of the interaction between individual and parental history of melanoma resulted in MII = 1.46 (95% CI 1.06 to 2.03, P = 0.03) and ICR = 21.7 (95% CI 13.3–33.3, P < 0.01), thus suggesting greater than multiplicative and greater than additive interaction effects.

Table 2 shows the relative risks of site-specific cancers for individuals with a parental family history of the particular cancer (first column) and the parental risks of the same (concordant) cancer after melanoma. For example, the relative risk of liver cancer was 1.3 for the offspring of liver cancer patients, but the SIR increased to 13.5 (two cases) when the offspring were melanoma patients. The relative risk of breast cancer in women with affected mothers was 1.64, and it increased to 2.51 among melanoma patients with a maternal history of breast cancer. The interaction between ‘individual history of melanoma’ and ‘maternal history of breast cancer’ did not significantly depart from multiplicativity or additivity (MII = 1.13 (95% CI 0.79–1.64, P = 0.29) and ICR = 0.52 (95% CI 0.24–1.59, P = 1.14)). Melanoma patients with a

| Table 1 | Relative risks of second neoplasms after melanoma in the general population and in patients with a parental history of melanoma |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
| Type of second cancer | All offspring | Offspring of melanoma patients |
| | N | SIR | (95% CI) | N | SIR | (95% CI) |
| Any type | 1156 | 1.74 | 1.64–1.85 | 53 | 3.59 | 2.69–4.69 |
| Solid cancers | 1089 | 1.76 | 1.66–1.87 | 51 | 3.71 | 2.76–4.88 |
| Upper aerodigestive tract | 16 | 1.50 | 0.86–2.45 | 1 | 4.12 | 0.00–23.6 |
| Colorectum | 54 | 0.99 | 0.74–1.29 | 1 | 0.88 | 0.00–5.06 |
| Liver | 11 | 1.19 | 0.59–2.14 | 0 | 1 | 4.46 | 0.00–25.6 |
| Pancreas | 13 | 1.17 | 0.62–2.07 | 1 | 2.33 | 0.22–8.59 |
| Lung | 34 | 0.82 | 0.57–1.15 | 5 | 1.46 | 0.46–3.44 |
| Breast | 206 | 1.35 | 1.17–1.55 | 1 | 2.30 | 0.00–13.2 |
| Endometrium | 17 | 0.73 | 0.42–1.17 | 0 | 1 | 1.51 | 0.29–4.48 |
| Ovary | 16 | 0.83 | 0.47–1.34 | 3 | 3.27 | 0.00–18.7 |
| Prostate | 111 | 1.22 | 1.01–1.47 | 1 | 3 | 2.99 | 0.00–17.1 |
| Kidney | 22 | 1.54 | 0.96–2.34 | 2 | 3.14 | 0.30–11.6 |
| Urinary bladder | 30 | 1.32 | 0.89–1.89 | 0 | 1 | 0.56 | 0.00–17.6 |
| Melanoma | 343 | 9.03 | 8.10–10.0 | 32 | 32.3 | 22.1–45.6 |
| Skin, squamous cell | 53 | 3.48 | 2.61–4.56 | 1 | 2.99 | 0.00–17.1 |
| Nervous system | 43 | 1.66 | 1.20–2.24 | 2 | 3.14 | 0.30–11.6 |
| Lymphohaematopoietic neoplasms | 67 | 1.50 | 1.16–1.90 | 2 | 1.92 | 0.18–7.07 |
| Non-Hodgkin’s lymphoma | 33 | 1.60 | 1.10–2.26 | 3 | 2.51 | 1.62–3.71 |
| Myeloma | 11 | 1.66 | 0.83–2.98 | 1 | 3 | 3.07 | 0.00–17.6 |
| Leukaemia | 16 | 1.06 | 0.60–1.72 | 1 | 2.85 | 0.00–16.3 |

- Number of melanoma patients with second neoplasms. Standardised Incidence Ratio. Confidence interval. Bold type represents statistical significance at the 0.05 confidence level.

| Table 2 | Parental relative risks of cancer and relative risks of second neoplasms in melanoma patients with a parental history of concordant (same site) cancer |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
| Type of second cancer | Individuals with parents affected by concordant cancer | Melanoma patients with parents affected by concordant cancer |
| | N | SIR | (95% CI) | N | SIR | (95% CI) |
| Any type | 81548 | 1.05 | 1.05–1.06 | 629 | 1.93 | 1.78–2.09 |
| Solid cancers | 71104 | 1.06 | 1.05–1.07 | 557 | 1.95 | 1.79–2.12 |
| Upper aerodigestive tract | 49 | 1.67 | 1.26–2.22 | 3 | 0.76 | 0.14–2.25 |
| Colon rectum | 1573 | 1.69 | 1.61–1.78 | 2 | 13.5 | 1.28–49.8 |
| Liver | 60 | 1.30 | 1.01–1.69 | 1 | 4.82 | 0.00–27.7 |
| Pancreas | 85 | 2.01 | 1.62–2.50 | 1 | 0.56 | 0.00–3.20 |
| Lung | 647 | 1.72 | 1.58–1.86 | 25 | 2.51 | 1.62–3.71 |
| Breast | 3656 | 1.64 | 1.59–1.70 | 1 | 3.07 | 0.00–17.6 |
| Endometrium | 163 | 2.16 | 1.85–2.52 | 0 | 1 | 0.80 | 0.00–3.20 |
| Ovary | 176 | 2.48 | 2.13–2.88 | 1 | 11 | 1.57 | 0.78–2.82 |
| Prostate | 2472 | 1.88 | 1.80–1.96 | 11 | 3 | 1.31 | 2.47–38.7 |
| Kidney | 119 | 2.19 | 1.82–2.62 | 3 | 3.25 | 0.30–12.0 |
| Urinary bladder | 279 | 1.79 | 1.58–2.01 | 2 | 13.3 | 22.1–45.6 |
| Melanoma | 438 | 2.44 | 2.22–2.68 | 32 | 32.3 | 22.1–45.6 |
| Skin, squamous cell | 172 | 2.03 | 1.74–2.36 | 2 | 4.04 | 0.38–14.8 |
| Nervous system | 257 | 1.69 | 1.50–1.92 | 1 | 2.23 | 0.00–12.8 |
| Lymphohaematopoietic neoplasms | 879 | 1.38 | 1.29–5 | 2.83 | 0.89 | 6.65 |
| Non-Hodgkin’s lymphoma | 167 | 1.86 | 1.60–2.17 | 2 | 6.33 | 0.60–23.3 |
| Myeloma | 35 | 2.43 | 1.74–3.40 | 0 | 1 | 0.56 | 0.00–17.6 |
| Leukaemia | 150 | 1.87 | 1.58–2.19 | 1 | 4.47 | 0.00–25.7 |

- Number of cases with a parental history. Standardised Incidence Ratio. Confidence interval. Bold type represents statistical significance at the 0.05 confidence level.
parental history of kidney cancer were at very high risk of developing second kidney cancers (SIR 13.1, three cases).

**DISCUSSION**

The present study, based on the nation-wide Swedish Family-Cancer Database, focuses on the risk of subsequent cancer after malignant melanoma in individuals with a parental history of cancer. In agreement with previous studies, melanoma patients were at an increased risk of second tumours, including melanomas and lymphomas. The reasons for these increases are probably manifold. Immune suppression induced by therapy, exposure to ultraviolet radiation and the primary disease could explain some cases, particularly for non-Hodgkin’s lymphoma (Ebbesen, 1981; Romedahl et al., 1988; Hemminki et al., 2003). A novel result of this study was the increased risk observed for squamous cell carcinoma. This association has been previously observed in a reversed sequence: increased risk of melanoma after squamous cell carcinoma (Hemminki and Dong, 2000). In addition to treatment-related factors, unidentified susceptibility genes could explain these results to some extent. Inactivation of CDKN2A by genetic and epigenetic changes has been described in melanoma, squamous cell carcinoma, breast cancer and Hodgkin disease (Soufir et al., 1999; Brown et al., 2004; Debniaik et al., 2007; Sinha et al., 2008). However, the association between germline mutations in CDKN2A and malignancies other than melanoma are still unclear. Mutations in MC1R, a low-penetrance melanoma-predisposing gene, could also be involved in squamous cell skin cancers and in Hodgkin’s disease (Palmer et al., 2000; Box et al., 2001; Figl et al., 2007). The novel data from the present study refer to the risk of second concordant tumours in melanoma patients with a parental history of cancer. The risks were increased for second liver and kidney cancers after melanoma when the parents were diagnosed with liver or kidney cancer, respectively; however, the number of cases was small. More convincingly, a greater than additive and greater than multiplicative interaction was observed between parental and individual history of melanoma, with an expected SIR of 2.44 × 8.41 = 20.5 and an observed SIR of 32.3 (the SIR of second melanoma for individuals without a parental history was 8.41, 311 cases, 95% confidence interval: 7.50–9.40, data not shown). A study based on a previous version of the Database showed that, when mothers had breast cancer and fathers melanoma, the offspring was at a high risk of both breast cancer and melanoma (Hemminki and Vattinenen, 1997). The present data could mirror the effects of gene-environment interactions – for example, between CDKN2A mutations and UV-exposure – or the combinations among yet unidentified susceptibility genes.

**ACKNOWLEDGEMENTS**

This study was supported by Deutsche Krebshilfe, the Swedish Cancer Society, the EU, LSHC-CT-2004-503465 and the Swedish Council for Working Life and Social Research. The Family-Cancer Database was created by linking registers maintained at Statistics Sweden and the Swedish Cancer Registry.

**REFERENCES**

Bhatia S, Estrada-Batres L, Maryon T, Bogue M, Chu D (1999) Second primary tumours in patients with cutaneous malignant melanoma. _Cancer_ 86: 2014–2020

Box NF, Duffy DL, Irving RE, Russell A, Chen W, Griffiths LR, Parsons PG, Green AC, Sturm RA (2001) Melanocortin-1 receptor genotype is a risk factor for basal and squamous cell carcinoma. _J Invest Dermatol_ 116: 224–229

Brown VL, Harwood CV, Crook T, Cronin JG, Kelsell DR, Proby CM (2004) A novel result of this study was the increased risk observed for squamous cell carcinoma. _J Invest Dermatol_ 122: 1284–1292

Debniaik T, Cybulski C, Gorski B, Huzarski T, Byrski T, Gronwald J, Jakubowska A, Kowalska E, Oszurek O, Narod SA, Lubinski J (2007) CDKN2A-positive breast cancers in young women from Poland. _Breast Cancer Res Treat_ 103: 355–359

de Vries E, Goebber JW (2004) Cutaneous malignant melanoma in Europe. _Eur J Cancer_ 40: 2355–2366

Ebbesen P (1981) Enhanced lymphoma incidence in BALB/c mice after ultraviolet treatment. _J Natl Cancer Inst_ 67: 1077–1078

Figl A, Thirumaran RK, Ugurel S, Gast A, Hemminki K, Kumar R, Schadendorf D (2007) Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants. _Arch Dermatol_ 143: 495–499

Goggins WB, Tsao H (2003) A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma Survivors. _Cancer_ 97: 639–643

Hemminki K, Vahtinen P (1997) Interaction of breast cancer and melanoma genotypes. _Lancet_ 350: 931–932

Hemminki K, Dong C (2000) Subsequent cancers after _in situ_ and invasive squamous cell carcinoma of the skin. _Arch Dermatol_ 136: 647–651

Hemminki K, Jiang Y, Steineck G (2003) Skin cancer and non-Hodgkin’s lymphoma as second malignancies, markers of impaired immune function? _Eur J Cancer_ 39: 223–229

Hemminki K, Granström C, Sundquist J, Lorenzo Bermejo J (2006) The updated Swedish family-cancer database used to assess familial risks of prostate cancer during rapidly increasing incidence. _Heredit Cancer in Clin Pract_ 4: 186–192

Miller AJ, Mihm Jr MC (2006) Melanoma. _N Engl J Med_ 355: 51–65

Palmer JS, Duffy DL, Box NF, Aitken JF, O’Gorman LE, Green AC, Hayward NK, Martin NG, Sturm RA (2000) Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? _Am J Hum Genet_ 66: 176–186

Romedahl CA, Donahvo C, Fidler IJ, Kripke ML (1988) Effect of ultraviolet-B radiation on the in vivo growth of murine melanoma cells. _Cancer Res_ 48: 4007–4010

Schmidt-Wendtner M-H, Baumert J, Wendtner C-M, Plewig G, Volkenandt M (2001) Risk of second primary malignancies in patients with cutaneous melanoma. _Br J Dermatol_ 145: 981–985

Sinha S, Chunder N, Mukherjee N, Alam N, Roy A, Roychoudhury S, Kumar Panda C (2008) Frequent deletion and methylation in SHHGL2 and CDKN2A loci are associated with early- and late-onset breast carcinoma. _Ann Surg Oncol_ 15(4): 1070–1080

Soufir N, Molks JP, Vilmer C, Moch C, Verola O, Rivet J, Tesniere A, Dubertret L, Basset-Seguin N (1999) P16 UV mutations in human skin epithelial tumors. _Oncogene_ 18: 5477–5481